Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy and Safety of the Irinotecan, Capecitabine, and Oxaliplatin (Iox) Regimen in Metastatic Gastric Cancer: A Single Arm Phase Ii Trial



Anvari S1 ; Alimoghaddam K1 ; Kasaeian A1 ; Vaezi M1 ; Rajaeinejad M2 ; Zokaasadi M1 ; Fumani HK1 ; Ghavamzadeh A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. AJA Cancer Epidemiology Research and Treatment Center (AJA-CERTC), AJA University of Medical Sciences, Tehran, Iran

Source: Middle East Journal of Cancer Published:2019

Abstract

Background: Gastric cancer is one of the most common malignancies worldwide with a high case mortality rate. In metastatic gastric cancer, a proper combination of chemotherapy could increase the survival rate. The goal of this study is to evaluate the efficacy and safety of the combination regimen of irinotecan, oxaliplatin, and Xeloda in metastatic gastric cancer. Methods: A total of 45 patients with metastatic gastric cancer and good performance status according to the Eastern Cooperative Oncology Group (score: 0-1) received the irinotecan, oxaliplatin, and Xeloda chemotherapy regimen. Demographic data, responses to treatment, and adverse effects were gathered for all cases. Overall survival and progression-free survival rates for patients were calculated using the Kaplan-Meier estimate. Results: Patients’ mean age was 58.3 ± 11.3 years (range: 24-81). There were 73.4% male patients and 26.6% female patients. Anorexia and weight loss were the most common symptoms. Overall response rate was 50%. The majority of toxicities were anemia, nausea and vomiting (grades 1 and 2), diarrhea (grades 1 and 2), neutropenia, alopecia, and hand and foot syndrome. The one-year progression-free survival rate was 31.5 ± 7.5%, whereas the two-year progression-free survival rate was zero. The one-year overall survival rate was 34.91 ± 8.5%. Patients had a two-year overall survival rate of 7.7 ± 6.6%. Diffuse type cancer was linked to an inferior outcome. Conclusion: Regardless of our limited number of patients, this combination could be a suitable regimen for metastatic gastric cancer in terms of low toxicity, acceptable response rate, and survival results. © 2019, Shiraz University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
2. Annual Trends of Gastrointestinal Cancers Mortality in Iran During 1990-2015; Nasbod Study, Archives of Iranian Medicine (2018)
3. Two Novel Compounds With Tri-Aryl Structures As Effectivanti-Breast Cancer Candidates In-Vivo, Iranian Journal of Pharmaceutical Research (2020)
4. Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma, Journal of Cellular Biochemistry (2019)
5. Prevalence of Gastric Precancerous Lesions Among Chronic Dyspeptic Patients and Related Common Risk Factors, European Journal of Cancer Prevention (2015)
6. Epidemiology of Head and Neck Cancers in Northern Iran: A 10-Year Trend Study From Golestan Province, Archives of Iranian Medicine (2018)
7. Risk of Gastric Cancer by Water Source: Evidence From the Golestan Case-Control Study, PLoS ONE (2015)
8. A Review of Incidence and Mortality of Colorectal, Lung, Liver, Thyroid, and Bladder Cancers in Iran and Compared to Other Countries, Wspolczesna Onkologia (2019)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (6)
Hojjat Zeraati (2)
Other Related Docs
9. Relationship of Amplification and Expression of the C-Myc Gene With Survival Among Gastric Cancer Patients, Asian Pacific Journal of Cancer Prevention (2015)
10. Estimating the Economic Burden of Premature Mortality Caused by Cancer in Iran: 2006-2010, Asian Pacific Journal of Cancer Prevention (2016)
11. The Correlation Between Egfr and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer, Anti-Cancer Agents in Medicinal Chemistry (2019)
12. Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?, Frontiers in Oncology (2021)
13. Postoperative Net Survival of Gastric Adenocarcinoma at Imam Khomeini Hospital in Tehran: Estimating in a Relative-Survival Framework, Koomesh (2018)
14. Evaluation of Serum Vitamin B12 Levels in Patients With Colon and Breast Cancer: A Case-Control Study, International Journal of Hematology-Oncology and Stem Cell Research (2023)
15. Current Status and Future Prospects for Esophageal Cancer, Cancers (2023)
16. Seroprevalence of Herpes Simplex Virus Type 2 and Human Herpesvirus Type 8 Among Prostate Cancer Patients Compared to Cancer-Free Men, International Journal of Cancer Management (2021)
17. Estimating the Net Survival of Patients With Gastric Cancer in Iran in a Relative Survival Framework, Iranian Journal of Medical Sciences (2018)
18. The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population, Avicenna Journal of Medical Biotechnology (2020)
19. Synthesis and Evaluation of a Novel Nanosized Anionic Linear Globular Dendrimer G2-Ciprofloxacin Conjugate Against Prostate Cancer, Pakistan Journal of Pharmaceutical Sciences (2020)
20. Occupational Exposure to Wood Dust and Risk of Nasopharyngeal Cancer: A Systematic Review and Meta-Analysis, Environmental Research (2019)
21. Evaluation of the Trends of Stomach Cancer Incidence in Districts of Iran From 2000-2010: Application of a Random Effects Markov Model, Asian Pacific Journal of Cancer Prevention (2016)
22. Microrna-Induced Drug Resistance in Gastric Cancer, Biomedicine and Pharmacotherapy (2015)